CAPR - CIK 0001133869
The table below shows CAPRICOR THERAPEUTICS, INC.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$69.81M | -$40.00M | -$25.60M | $4.92M | -$16.81M | -$10.05M |
| Capital expenditure | $2.90M | $1.17M | $1.31M | $2.00M | $1.20M | $547.60K |
| Investing cash flow | $97.48M | -$116.18M | $5.11M | -$35.07M | -$1.20M | $5.44M |
| Dividends paid | - | - | - | - | - |
CAPRICOR THERAPEUTICS, INC. reported operating cash flow of -$69.81M for fiscal year 2025. That is down 74.5% from -$40.00M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$14.45M (FY 2016) to -$69.81M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | $0.00 |
| Financing cash flow | $248.89M | $152.77M | $25.58M | $4.87M | $20.23M | $33.38M |